China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that the National Medical Products Administration (NMPA) has accepted the market filing for its Category 1 product TQ-B3101 for the treatment of ROS1-positive non-small cell lung cancer (NSCLC).
Drug Mechanism and Efficacy
TQ-B3101 is a small molecule inhibitor targeting tyrosine kinase ROS1/ALK/c-Met. It selectively inhibits the proliferation of ROS1-positive, ALK-positive, and c-Met tumor cells, induces G1 cell cycle arrest, and promotes apoptosis, thereby improving the survival prognosis of NSCLC patients. Clinical data indicates TQ-B3101 demonstrates significant therapeutic effects in both short- and long-term NSCLC treatment, with low ocular toxicity and a favorable safety profile.-Fineline Info & Tech
